Ebola: an analysis of immunity at the molecular level

The 2014 Ebola outbreak in West Africa raised global concern requiring concerted effort from the worldwide scientific community to analyze immune responses, in natural infection and in the context of vaccination and therapy. Herein we review and analyze antibody and T cell epitope data reported in the scientific literature. More than 100 epitopes have been defined for viruses within the Filoviridae family, 73% of which are specific to Zaire ebolavirus (EBOV). While data are available for all EBOV proteins, the vast majority of epitopes relate to the surface glycoprotein, GP. Several neutralizing and/or protective sites are defined for monoclonal antibodies, including those used in the therapeutic cocktails ZMAb, MB-003 and ZMapp. However, little human and non-human primate data (NHP) are currently available, highlighting a crucial gap, especially at the level of T cell responses. To fill this gap, we provide sets of predicted human and macaque CD4+ and CD8+ restricted T cell epitopes, covering most common MHC variants expressed in humans and NHPs and conserved within the EBOV species. This comprehensive analysis of molecular targets of the immune response to EBOV should assist the scientific community in the evaluation of the EBOV-specific immune response in infection, therapy and vaccination.

[1]  D. Weiner,et al.  A Single Dose Respiratory Recombinant Adenovirus-Based Vaccine Provides Long-Term Protection for Non-Human Primates from Lethal Ebola Infection , 2014, Molecular pharmaceutics.

[2]  Deborah Hix,et al.  The immune epitope database (IEDB) 3.0 , 2014, Nucleic Acids Res..

[3]  Robert T. Chen,et al.  The Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG). , 2015, Vaccine.

[4]  Christopher Dye,et al.  Ebola vaccine--an urgent international priority. , 2014, The New England journal of medicine.

[5]  A. Ansari.  Clinical features and pathobiology of Ebolavirus infection. , 2014, Journal of autoimmunity.

[6]  X. Qiu,et al.  Structures of protective antibodies reveal sites of vulnerability on Ebola virus , 2014, Proceedings of the National Academy of Sciences.

[7]  David Haussler,et al.  The UCSC Ebola Genome Portal , 2014, PLoS currents.

[8]  G. Gao,et al.  Molecular Characterization of the Monoclonal Antibodies Composing ZMAb: A Protective Cocktail Against Ebola Virus , 2014, Scientific Reports.

[9]  OliphantErin.  Ebola Hemorrhagic Fever: Genetic Biomarkers and Vaccine Development , 2014 .

[10]  A. Sette,et al.  Conservancy of mAb Epitopes in Ebolavirus Glycoproteins of Previous and 2014 Outbreaks , 2014, PLoS currents.

[11]  Jon Cohen,et al.  Infectious diseases. The Ebola vaccine underdog. , 2014, Science.

[12]  Stephan Günther,et al.  Emergence of Zaire Ebola virus disease in Guinea. , 2014, The New England journal of medicine.

[13]  John Sidney,et al.  Development and validation of a broad scheme for prediction of HLA class II restricted T cell epitopes , 2014, BCB.

[14]  Rachel S. G. Sealfon,et al.  Genomic surveillance elucidates Ebola virus origin and transmission during the 2014 outbreak , 2014, Science.

[15]  X. Qiu,et al.  Immunization with vesicular stomatitis virus vaccine expressing the Ebola glycoprotein provides sustained long-term protection in rodents , 2014, Vaccine.

[16]  J. Strong,et al.  Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp™ , 2014, Nature.

[17]  Bjoern Peters,et al.  Immunodominance Changes as a Function of the Infecting Dengue Virus Serotype and Primary versus Secondary Infection , 2014, Journal of Virology.

[18]  Erin E. H. Tran,et al.  Spatial Localization of the Ebola Virus Glycoprotein Mucin-Like Domain Determined by Cryo-Electron Tomography , 2014, Journal of Virology.

[19]  E. Leroy,et al.  Identification of Continuous Human B-Cell Epitopes in the VP35, VP40, Nucleoprotein and Glycoprotein of Ebola Virus , 2014, PloS one.

[20]  E. Oliphant.  Ebola hemorrhagic fever: genetic biomarkers and vaccine development. , 2014, Genetic testing and molecular biomarkers.

[21]  Kazutaka Katoh,et al.  MAFFT: iterative refinement and additional methods. , 2014, Methods in molecular biology.

[22]  Bjoern Peters,et al.  HLA Class I Alleles Are Associated with Peptide-Binding Repertoires of Different Size, Affinity, and Immunogenicity , 2013, The Journal of Immunology.

[23]  X. Qiu,et al.  Sustained protection against Ebola virus infection following treatment of infected nonhuman primates with ZMAb , 2013, Scientific Reports.

[24]  Joshua C. Johnson,et al.  Therapeutic Intervention of Ebola Virus Infection in Rhesus Macaques with the MB-003 Monoclonal Antibody Cocktail , 2013, Science Translational Medicine.

[25]  J. Dye,et al.  Persistent immune responses after Ebola virus infection. , 2013, The New England journal of medicine.

[26]  Gary P Kobinger,et al.  Induction of broad cytotoxic T cells by protective DNA vaccination against Marburg and Ebola. , 2013, Molecular therapy : the journal of the American Society of Gene Therapy.

[27]  Heinz Feldmann,et al.  Filoviridae: Marburg and ebola viruses , 2013 .

[28]  Ravi V. Kolla,et al.  Comprehensive analysis of dengue virus-specific responses supports an HLA-linked protective role for CD8+ T cells , 2013, Proceedings of the National Academy of Sciences.

[29]  J. Sidney,et al.  Peptide-binding motifs associated with MHC molecules common in Chinese rhesus macaques are analogous to those of human HLA supertypes and include HLA-B27-like alleles , 2013, Immunogenetics.

[30]  M. Katze,et al.  Antibodies are necessary for rVSV/ZEBOV-GP–mediated protection against lethal Ebola virus challenge in nonhuman primates , 2013, Proceedings of the National Academy of Sciences.

[31]  X. Qiu,et al.  Immune Parameters Correlate with Protection Against Ebola Virus Infection in Rodents and Nonhuman Primates , 2012, Science Translational Medicine.

[32]  Lisa Hensley,et al.  Delayed treatment of Ebola virus infection with plant-derived monoclonal antibodies provides protection in rhesus macaques , 2012, Proceedings of the National Academy of Sciences.

[33]  Ravi V. Kolla,et al.  T Cell Responses to Known Allergen Proteins Are Differently Polarized and Account for a Variable Fraction of Total Response to Allergen Extracts , 2012, The Journal of Immunology.

[34]  X. Qiu,et al.  Successful Treatment of Ebola Virus–Infected Cynomolgus Macaques with Monoclonal Antibodies , 2012, Science Translational Medicine.

[35]  Philip E. Bourne,et al.  Immune epitope database analysis resource , 2012, Nucleic Acids Res..

[36]  J. Greenbaum,et al.  Dissecting Mechanisms of Immunodominance to the Common Tuberculosis Antigens ESAT-6, CFP10, Rv2031c (hspX), Rv2654c (TB7.7), and Rv1038c (EsxJ) , 2012, The Journal of Immunology.

[37]  Virgil L. Woods,et al.  Structural Basis for Differential Neutralization of Ebolaviruses , 2012, Viruses.

[38]  X. Qiu,et al.  Characterization of Zaire ebolavirus glycoprotein-specific monoclonal antibodies. , 2011, Clinical immunology.

[39]  Mario Roederer,et al.  CD8+ cellular immunity mediates rAd5 vaccine protection against Ebola virus infection of nonhuman primates , 2011, Nature Medicine.

[40]  Bjoern Peters,et al.  Functional classification of class II human leukocyte antigen (HLA) molecules reveals seven different supertypes and a surprising degree of repertoire sharing across supertypes , 2011, Immunogenetics.

[41]  P. Iversen,et al.  Advanced antisense therapies for postexposure protection against lethal filovirus infections , 2010, Nature Medicine.

[42]  Joshua C. Johnson,et al.  Postexposure protection of non-human primates against a lethal Ebola virus challenge with RNA interference: a proof-of-concept study , 2010, The Lancet.

[43]  Bjoern Peters,et al.  The most common Chinese rhesus macaque MHC class I molecule shares peptide binding repertoire with the HLA-B7 supertype , 2010, Immunogenetics.

[44]  E. Saphire,et al.  Ebolavirus glycoprotein structure and mechanism of entry. , 2009, Future virology.

[45]  N. Sullivan,et al.  Correlates of protective immunity for Ebola vaccines: implications for regulatory approval by the animal rule , 2009, Nature Reviews Microbiology.

[46]  Heinz Feldmann,et al.  Disease modeling for Ebola and Marburg viruses , 2009, Disease Models & Mechanisms.

[47]  W. Kalina,et al.  Discovery of common marburgvirus protective epitopes in a BALB/c mouse model , 2009, Virology Journal.

[48]  David Haussler,et al.  Using native and syntenically mapped cDNA alignments to improve de novo gene finding , 2008, Bioinform..

[49]  P. Jahrling,et al.  Recombinant human activated protein C for the postexposure treatment of Ebola hemorrhagic fever. , 2007, The Journal of infectious diseases.

[50]  Wei Li,et al.  Development of an epitope conservancy analysis tool to facilitate the design of epitope-based diagnostics and vaccines , 2007, BMC Bioinformatics.

[51]  D. Burton,et al.  Neutralizing Antibody Fails to Impact the Course of Ebola Virus Infection in Monkeys , 2007, PLoS pathogens.

[52]  L. Fernando,et al.  Effective Post-Exposure Treatment of Ebola Infection , 2007, PLoS pathogens.

[53]  G. Kobinger,et al.  Chimpanzee adenovirus vaccine protects against Zaire Ebola virus. , 2006, Virology.

[54]  J. Dye,et al.  Protective Cytotoxic T-Cell Responses Induced by Venezuelan Equine Encephalitis Virus Replicons Expressing Ebola Virus Proteins , 2005, Journal of Virology.

[55]  D. Swenson,et al.  Induction of Humoral and CD8+ T Cell Responses Are Required for Protection against Lethal Ebola Virus Infection1 , 2005, The Journal of Immunology.

[56]  R. Ahmed,et al.  Persistent Infection with Ebola Virus under Conditions of Partial Immunity , 2004, Journal of Virology.

[57]  P. Jahrling,et al.  Treatment of Ebola virus infection with a recombinant inhibitor of factor VIIa/tissue factor: a study in rhesus monkeys , 2003, The Lancet.

[58]  M. K. Hart.  Vaccine research efforts for filoviruses. , 2003, International journal for parasitology.

[59]  D. Burton,et al.  Pre- and Postexposure Prophylaxis of Ebola Virus Infection in an Animal Model by Passive Transfer of a Neutralizing Human Antibody , 2002, Journal of Virology.

[60]  M. K. Hart,et al.  Protection from Ebola Virus Mediated by Cytotoxic T Lymphocytes Specific for the Viral Nucleoprotein , 2001, Journal of Virology.

[61]  J. Wilson,et al.  Epitopes involved in antibody-mediated protection from Ebola virus. , 2000, Science.

[62]  S. Hazar,et al.  Filoviridae: Marburg and Ebola viruses. , 2000 .

[63]  P. Debré,et al.  Defective humoral responses and extensive intravascular apoptosis are associated with fatal outcome in Ebola virus-infected patients , 1999, Nature Medicine.

[64]  A. Rowe,et al.  Clinical virology of Ebola hemorrhagic fever (EHF): virus, virus antigen, and IgG and IgM antibody findings among EHF patients in Kikwit, Democratic Republic of the Congo, 1995. , 1999, The Journal of infectious diseases.